Physician profile
Andre Saad
NPI 1124259213
$2,746.80
in general payments reported to CMS, 2019-2025
12 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $364 · 2021: $426 · 2022: $507 · 2023: $280 · 2024: $296 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.60 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,358.41 | 2019-2024 | Assurity, Aveir |
| Artivion, INC. | $284.00 | 2019 | |
| Edwards Lifesciences Corporation | $166.39 | 2022 | |
| Medtronic, INC. | $161.41 | 2023-2025 | Micra |
| Astrazeneca Pharmaceuticals LP | $146.29 | 2019-2023 | Farxiga |
| Pfizer INC. | $126.47 | 2019 | |
| Boston Scientific Corporation | $116.55 | 2020 | |
| Inari Medical, INC. | $112.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.40 | 2025 | |
| Novo Nordisk INC | $90.15 | 2020 | |
| Janssen Pharmaceuticals, INC | $65.18 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.